Format

Send to

Choose Destination
Breast. 2015 Feb;24(1):51-6. doi: 10.1016/j.breast.2014.11.006. Epub 2014 Dec 6.

Acceptance and adherence to chemoprevention among women at increased risk of breast cancer.

Author information

1
H. Lee Moffitt Cancer Center & Research Institute, USA; U. of South Florida, Department of Family Medicine, USA. Electronic address: rroetzhe@health.usf.edu.
2
U. of New Mexico Cancer Center, USA.
3
H. Lee Moffitt Cancer Center & Research Institute, USA.

Abstract

BACKGROUND:

Chemoprevention is an option for women who are at increased risk of breast cancer (five year risk ≥1.7%). It is uncertain, however, how often women accept and complete five years of therapy and whether clinical or demographic factors predict completion.

METHODS:

Medical records were abstracted for 219 women whose five year risk of breast cancer was ≥1.7% and who were offered chemoprevention while attending a high risk breast clinic at the Moffitt Cancer Center. We examined the likelihood of accepting chemoprevention and completing five years of therapy, and potential clinical and demographic predictors of these outcomes, using multivariable logistic regression and survival analysis models.

RESULTS:

There were 118/219 women (54.4%) who accepted a recommendation for chemoprevention and began therapy. The likelihood of accepting chemoprevention was associated with lifetime breast cancer risk and was higher for women with specific high risk conditions (lobular carcinoma in situ and atypical ductal hyperplasia). Women with osteoporosis and those that consumed alcohol were also more likely to accept medication. There were 58/118 (49.2%) women who stopped medication at least temporarily after starting therapy. Based on survival curves, an estimated 60% of women who begin chemoprevention will complete five years of therapy.

CONCLUSIONS:

A substantial percentage of women at increased risk of breast cancer will decline chemoprevention and among those that accept therapy, approximately 40% will not be able to complete five years of therapy because of side effects.

KEYWORDS:

Breast cancer; Breast cancer prevention; Chemoprevention; Lobular carcinoma in situ; Raloxifene; Tamoxifen

PMID:
25491191
PMCID:
PMC4503358
DOI:
10.1016/j.breast.2014.11.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center